Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 1R44DA061386-01 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute on Drug Abuse (NIDA) | NIH |
Not provided
Not provided
Not provided
Not provided
Our primary objective is to evaluate the ability of Boulder Care's telehealth-platform to create the necessary paradigmatic shift in Opioid Use Disorder (OUD) treatment to reach vulnerable populations, with targets that support both equitable and culturally-specific OUD treatment as well as business profitability.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Receiving Intervention | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Telemedicine Buprenorphine Treatment | Drug | With this NIDA-funded grant, the study team will identify app-based treatment workflows that are demonstrably effective in low-resource settings: namely, telehealth services that are accessible without high-speed internet and deliberately helping patients transition into OUD care from relevant health and community system settings. An intentional focus on rural areas and Black and Hispanic demographics will help enhance health equity, and support solutions for payors. |
| Measure | Description | Time Frame |
|---|---|---|
| Intervention Acceptability, Appropriateness, Feasibility | To measure the participant intervention experience, the study team will utilize qualitative interview data with study participants. These data will be organized into the implementation science categories: Acceptability of Intervention Measure (AIM), Intervention Appropriateness Measure (IAM), and Feasibility of Intervention Measure (FIM). The study team will determine whether each participant found the intervention to be feasible, acceptable, and/or appropriate. These findings will then be aggregated to better understand how participants experience the implementation of a telemedicine Opioid Use Disorder treatment organization, and will inform a future scaled-up implementation. | 48 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| CDC's Health-Related Quality of Life - 4 (CDC HRQOL-4, also called the "Healthy Days Measures") | Items include: self-rated health, physically unhealthy days, mentally unhealthy days, and activity limitation days. Values: Self-rated health: 1 = Excellent, 2 = Very good, 3 = Good, 4 = Fair, 5 = Poor → Minimum = 1 (Excellent), Maximum = 5 (Poor) Unhealthy days (physical/mental): Range 0-30 days in past 30 days → Minimum = 0, Maximum = 30 Direction: Higher scores = worse outcomes (more unhealthy days or poorer self-rated health). |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Andrea Baron, MPH | Contact | 408-483-2766 | andrea.baron@boulder.care | |
| Laura Monico, PhD | Contact | 855-605-8816 | laura.monico@boulder.care |
| Name | Affiliation | Role |
|---|---|---|
| Andrea Baron, MPH | Boulder Care | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Boulder Care | Recruiting | Portland | Oregon | 97204 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 28851459 | Background | Weiner BJ, Lewis CC, Stanick C, Powell BJ, Dorsey CN, Clary AS, Boynton MH, Halko H. Psychometric assessment of three newly developed implementation outcome measures. Implement Sci. 2017 Aug 29;12(1):108. doi: 10.1186/s13012-017-0635-3. |
Not provided
Not provided
There are no plans to share individual participant data (IPD) from this study. Only aggregate study results will be reported.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009293 | Opioid-Related Disorders |
| ID | Term |
|---|---|
| D000079524 | Narcotic-Related Disorders |
| D019966 | Substance-Related Disorders |
| D064419 | Chemically-Induced Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| 48 weeks |
| Brief Addiction Monitor | Description: A 17-item multidimensional measure covering three domains:
Values:
Scoring and Direction:
| 48 weeks |
| Visual Analogue Opioid Craving Scale | Description: A single-item measure where participants rate their current intensity of craving for opioids by marking a point along a straight line (100 mm in length). The left anchor indicates "No craving at all" and the right anchor indicates "Most intense craving imaginable". Values: Minimum = 0 mm (no craving at all) Maximum = 100 mm (most intense craving imaginable) Direction: Higher scores = worse outcome (greater opioid craving) | 48 weeks |